Pharmafile Logo
Pharmafocus logo
Advanced Search

prostate cancer

Showing 15 posts of 92 posts found.

FDA grants priority review for Sanofi cancer drug

April 5, 2012
Research and Development, Sales and Marketing Erbitux, FDA, Regeneron, Sanofi, Zaltrap, colorectal cancer, prostate cancer

The FDA has granted Sanofi and partner Regeneron priority review for their colorectal cancer drug Zaltrap. Zaltrap (aflibercept) is seeking a …

News
NICE image

NICE recommends Xgeva for bone metastasis

March 29, 2012
Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer

NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …

News

Prostate cancer drug extends life after chemotherapy

March 29, 2012
Research and Development, Sales and Marketing Astellas, Medivation, Zytiga, prostate cancer

Prostate cancer treatment MDV3100 has been shown to extend life by nearly five months in men with advanced disease who …

News
Janssen's Zytiga

Janssen’s Zytiga launched in the UK

September 21, 2011
Sales and Marketing Zytiga, prostate cancer

Janssen’s new advanced prostate cancer treatment Zytiga has been launched in the UK. Zytiga (abiraterone acetate) has been shown in …

News
Zytiga

European approval for prostate cancer drug Zytiga

September 8, 2011
Sales and Marketing Janssen, Jevtana, Johnson & Johnson, Zytiga, prostate cancer

Johnson & Johnson’s Zytiga has been approved in the EU for late-stage prostate cancer. Zytiga (abiraterone acetate) is now licenced …

News
Bayer

FDA fast tracks Bayer prostate cancer drug

August 23, 2011
Sales and Marketing Algeta, Alpharadin, Bayer, prostate cancer

Bayer’s potential blockbuster prostate cancer drug Alpharadin has been granted a fast track review by the FDA, meaning it could …

News

Janssen’s prostate cancer drug gains European backing

July 26, 2011
Sales and Marketing Zytiga, prostate cancer

Janssen’s prostate cancer treatment Zytiga has been recommended by Europe’s CHMP, paving the way for possible third quarter launch. The …

News
Sanofi

Sanofi launches Jevtana in UK

July 6, 2011
Sales and Marketing Jevtana, Sanofi, prostate cancer

Sanofi has launched its promising advanced prostate cancer drug Jevtana in the UK following EMA approval in March. Jevtana (cabazitaxel) …

News

Prostate cancer drug Zytiga gains US approval

May 5, 2011
Sales and Marketing Centocor Ortho Biotech, Johnson & Johnson, Zytiga, prostate cancer

Zytiga a new treatment for the most hard to treat cases of prostate cancer has been approved in the US. …

News

GSK withdraws applications for Avodart

March 25, 2011
Research and Development Avodart, Cancer, GSK, bph, prostate cancer

GlaxoSmithKline has withdrawn all regulatory applications for Avodart to prevent prostate cancer after regulators raised doubts about its benefit/risk profile. …

News
Sanofi-Aventis HQ

Sanofi prostate cancer drug Jevtana approved in Europe

March 21, 2011
Sales and Marketing Jevtana, Sanofi-Aventis, TROPIC clinical trial, cabazitaxel, cancer drugs, chemotherapy, prostate cancer

Sanofi-Aventis’ new chemotherapy treatment Jevtana has followed up on its US approval last year by receiving the green light in …

News

Late-stage blow to AstraZeneca’s prostate cancer drug

February 7, 2011
Research and Development AstraZeneca, Cancer, prostate cancer, zibotentan

A late-stage trial of AstraZeneca’s oral prostate cancer drug zibotentan has been halted after it failed to meet its primary …

News

Success in pre-clinical microRNA treatment of prostate cancer

January 19, 2011
Research and Development MD Anderson Cancer Center, MicroRNA, Mirna Therapeutics, RNA interfering, miRNA, prostate cancer, rnai

A new MicroRNA treatment for prostate cancer has been highly effective against the disease in pre-clinical studies. MicroRNAs, or miRNAs, …

News

Bavarian Nordic courting cancer vaccine backers

November 12, 2010
Research and Development, Sales and Marketing Bavarian Nordic, Dendreon, Prostvac, Provenge, TroVax, cancer vaccine, prostate cancer, prostate cancer vaccine, zibotentan

Danish biotech Bavarian Nordic is in ‘advanced discussions’ with a number of potential pharma partners for its phase II therapeutic …

News

Late stage cancer drug failure for AstraZeneca

September 27, 2010
Sales and Marketing AstraZeneca, prostate cancer, zibotentan

AstraZeneca’s oncology pipeline has suffered a further blow after prostate cancer drug zibotentan failed to meet its primary endpoint of …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026